Incyte CorpINCY
Price$117.14Intrinsic value$120.042% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $120.04median of 6 methods · middle span $103-$244based on filings through 31 Mar 2026
Market Price $117.14Price as of 1 Oct 2026
Margin of Safety +2.5%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 7.7% (near-term consensus, capped) · years 2–5: 10.8%/yr (balance of the path).10.2% per year
Years 6–10: glide to demonstrated growth own history 32.3%, capped at 20%
Per-year rates
Yr 610.7%Yr 710.5%Yr 810.4%Yr 910.3%Yr 1010.2%
10.8% → 10.2%
Years 11–20: glide to long-run rate
Per-year rates
Yr 119.4%Yr 128.7%Yr 138.0%Yr 147.3%Yr 156.6%Yr 165.9%Yr 175.1%Yr 184.4%Yr 193.7%Yr 203.0%
10.2% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (6/7y) (limited history)32.3%
Discount rate (cost of equity) 8.7%
Volatility vs market (adjusted beta)0.84

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetIncyte CorpINCYHealth Care
Valuation
P/E16.5×
P/S4.8×
P/B4.8×
EV / Revenue4.2×
EV / EBITDA—
Profitability
Gross margin91.8%
Operating margin23.7%
Net margin26.7%
FCF margin25.2%
Returns
ROE25.5%
ROA19.5%
ROIC65.0%
Growth
Revenue growth (YoY)26.4%
5-yr fwd EPS growth10.2%
Financial strength
Debt / Equity0.01×
Current ratio3.68×
Altman Z-Score11.2
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.